Dai Y 2007.

Methods	Country: China Setting: hospital based Aim: to observe the therapeutic effect of Migu tablet on BMD, OPG, etc. in patients with postmenopausal osteoporosis Study design: randomised controlled trial Analysis: analysis of variance (F‐test) Loss to follow‐up: not reported
Participants	Ethnicity: Chinese 160 postmenopausal osteoporosis patients enrolled: 54 in Migu tablet trial group, 53 in Xianlinggubao group, 53 in compound calcium amino acid chelate capsules group Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: disease‐affected bone metabolism, endocrine diseases, etc
Interventions	Experimental: Migu tablet group: Migu tablet, 1 tablet, 3 times a day and compound calcium amino acid chelate capsule, 1 g, once a day; for 24 weeks Xianlinggubao group: Xianlinggubao capsule, 0.5, g 3 times a day and compound calcium amino acid chelate capsule, 1 g, once a day, for 24 weeks Control: compound calcium amino acid chelate capsule, 1 g, once a day, for 24 weeks
Outcomes	BMD
Notes	The study was supported by a health department funded project in Hubei Province, but no declarations of interest for the primary researchers was reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline comparison